Latest news with #minimallyInvasive
Yahoo
3 days ago
- Business
- Yahoo
GE HealthCare Stock Slips Despite the Launch of bkActiv S Series
GE HealthCare Technologies Inc. GEHC recently expanded its bkPortfolio family of Active Imaging systems with the launch of the bkActiv S Series, a next-generation ultrasound solution designed to guide non-surgical procedures in urology, colorectal care, and pelvic floor assessments. As demand grows for minimally invasive, office-based procedures, this new system supports real-time interventional guidance across key specialties. Built with direct input from physicians, the bkActiv S Series incorporates advanced transducer technology, intuitive controls, and a versatile, compact design suited for both hospital and outpatient environments. It enables single-handed operation, offers sterile draping options, and provides optimized workflows through adaptive imaging presets. With this launch, GE HealthCare further strengthens its leadership in point-of-care ultrasound, delivering performance and procedural efficiency without compromising on patient comfort or image quality. Shares of the company moved south 2.4% and closed at $71.14 yesterday following the announcement on Monday. In the year-to-date period, GEHC shares have lost 9.1% against the industry's 4.9% growth. The S&P 500 increased 1.2% in the same time frame. However, the launch of the bkActiv S Series strengthens GE HealthCare's long-term growth by deepening its presence in the fast-expanding market for minimally invasive, office-based procedures. As healthcare shifts toward cost-effective, outpatient care, this advanced imaging system positions GEHC to capture demand across urology, colorectal, and pelvic health practices. By expanding its bkPortfolio with solutions tailored for procedural guidance and physician efficiency, GEHC not only broadens its customer base but also builds recurring revenue opportunities through transducer sales, service contracts, and software upgrades. Meanwhile, GEHC currently has a market capitalization of $33.08 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. Image Source: Zacks Investment Research The bkActiv S Series is designed to empower clinicians with precise ultrasound guidance, delivering clear visualization of anatomical structures to support real-time decision-making during non-surgical procedures. It offers exceptional imaging quality alongside a modern, touch-based interface and includes Prostate Volume Assist, an AI-powered feature that automates prostate measurements, streamlining workflows and improving consistency. The system also enhances procedural confidence in urology and pelvic health by enabling quick image capture and optimized visualization. The interface includes GE HealthCare's TruSense technology and customizable layout options, allowing users to tailor the system to their preferences for efficiency and ease of use. Smart Button technology built into the transducers provides one-handed control, offering clinicians the ability to access multiple functions directly from the probe. High-resolution image capture is supported by advanced digital tools that enhance contrast and detail, while the Image Compare mode allows clinicians to view stored and live images side by side for real-time measurement and comparison. The system also integrates PRISM Technology, including the TruFocus algorithm for automatic image optimization, which improves detail clarity and supports consistent imaging quality. Adaptive Noise Suppression helps reduce background interference and enhances deep-tissue visualization by dynamically adjusting gain levels during scanning. Combined, these features make the bkActiv S Series well-suited for a variety of procedures, including prostate diagnostics, biopsies, and treatment guidance, in both hospital and office-based settings. In June, GE HealthCare launched MIM Encore, an integrated imaging software suite that enhances workflows and diagnostic precision across oncology, cardiology, and neurology. In May, it introduced CleaRecon DL, a deep-learning CBCT tool that improves image clarity in interventional procedures and received both FDA and CE approvals. Earlier in March, GEHC unveiled Freelium, a next-gen MRI platform using less than 1% helium, aimed at expanding sustainable imaging access. These developments reflect GEHC's ongoing push to combine advanced hardware with AI-powered imaging innovation. GEHC carries a Zacks Rank #4 (Sell) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
GE HealthCare Stock Slips Despite the Launch of bkActiv S Series
GE HealthCare Technologies Inc. GEHC recently expanded its bkPortfolio family of Active Imaging systems with the launch of the bkActiv S Series, a next-generation ultrasound solution designed to guide non-surgical procedures in urology, colorectal care, and pelvic floor assessments. As demand grows for minimally invasive, office-based procedures, this new system supports real-time interventional guidance across key specialties. Built with direct input from physicians, the bkActiv S Series incorporates advanced transducer technology, intuitive controls, and a versatile, compact design suited for both hospital and outpatient environments. It enables single-handed operation, offers sterile draping options, and provides optimized workflows through adaptive imaging presets. With this launch, GE HealthCare further strengthens its leadership in point-of-care ultrasound, delivering performance and procedural efficiency without compromising on patient comfort or image quality. Shares of the company moved south 2.4% and closed at $71.14 yesterday following the announcement on Monday. In the year-to-date period, GEHC shares have lost 9.1% against the industry's 4.9% growth. The S&P 500 increased 1.2% in the same time frame. However, the launch of the bkActiv S Series strengthens GE HealthCare's long-term growth by deepening its presence in the fast-expanding market for minimally invasive, office-based procedures. As healthcare shifts toward cost-effective, outpatient care, this advanced imaging system positions GEHC to capture demand across urology, colorectal, and pelvic health practices. By expanding its bkPortfolio with solutions tailored for procedural guidance and physician efficiency, GEHC not only broadens its customer base but also builds recurring revenue opportunities through transducer sales, service contracts, and software upgrades. Meanwhile, GEHC currently has a market capitalization of $33.08 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. Image Source: Zacks Investment Research The bkActiv S Series is designed to empower clinicians with precise ultrasound guidance, delivering clear visualization of anatomical structures to support real-time decision-making during non-surgical procedures. It offers exceptional imaging quality alongside a modern, touch-based interface and includes Prostate Volume Assist, an AI-powered feature that automates prostate measurements, streamlining workflows and improving consistency. The system also enhances procedural confidence in urology and pelvic health by enabling quick image capture and optimized visualization. The interface includes GE HealthCare's TruSense technology and customizable layout options, allowing users to tailor the system to their preferences for efficiency and ease of use. Smart Button technology built into the transducers provides one-handed control, offering clinicians the ability to access multiple functions directly from the probe. High-resolution image capture is supported by advanced digital tools that enhance contrast and detail, while the Image Compare mode allows clinicians to view stored and live images side by side for real-time measurement and comparison. The system also integrates PRISM Technology, including the TruFocus algorithm for automatic image optimization, which improves detail clarity and supports consistent imaging quality. Adaptive Noise Suppression helps reduce background interference and enhances deep-tissue visualization by dynamically adjusting gain levels during scanning. Combined, these features make the bkActiv S Series well-suited for a variety of procedures, including prostate diagnostics, biopsies, and treatment guidance, in both hospital and office-based settings. In June, GE HealthCare launched MIM Encore, an integrated imaging software suite that enhances workflows and diagnostic precision across oncology, cardiology, and neurology. In May, it introduced CleaRecon DL, a deep-learning CBCT tool that improves image clarity in interventional procedures and received both FDA and CE approvals. Earlier in March, GEHC unveiled Freelium, a next-gen MRI platform using less than 1% helium, aimed at expanding sustainable imaging access. These developments reflect GEHC's ongoing push to combine advanced hardware with AI-powered imaging innovation. GEHC carries a Zacks Rank #4 (Sell) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
3 days ago
- Business
- Globe and Mail
ISRG vs BSX: Which Medical Device Stock Has More Room to Run?
In a healthcare landscape increasingly shaped by technology, two names that stand out for their innovation and long-term potential are Intuitive Surgical ISRG and Boston Scientific BSX. Both companies are at the forefront of minimally invasive procedures — Intuitive as the undisputed leader in robotic-assisted surgery, and Boston Scientific as a powerhouse in interventional medical devices. With growing demand for advanced surgical solutions and aging global populations driving healthcare needs, investors are eyeing these med-tech giants as attractive long-term plays. But, which stock offers more compelling upside right now? Let's break down the fundamentals, growth trajectories, and market positions of ISRG and BSX to find out which one deserves a place in your portfolio. ISRG & BSX: Price Performance Intuitive Surgical represents a high-growth, high-premium pure play on robotic-assisted surgery. Its exceptional performance and growth provide compelling upside, but investors must accept margin compression and valuation risk in the short-to-medium term. Boston Scientific offers broader exposure to medical device innovation, with reliable growth driven by cardiovascular and interventional segments. It trades at a more moderate valuation and may appeal to investors seeking growth with less volatility. The year-to-date price performance of Intuitive Surgical has not been impressive, likely due to tariff concerns and rising competition from Chinese robotic device makers. However, BSX has outperformed ISRG likely due to its diversified business as well as strong U.S. demand. Shares of ISRG have lost 1.9% year to date, while those of BSX have gained 13.9%. Market Position & Core Offerings Intuitive Surgical dominates the surgical robotics niche with its flagship da???Vinci system, which continues to gain traction globally — 367 new units placed in the first quarter of 2025 alone, leading to a 17% year-over-year increase in procedures. Boston Scientific, by contrast, operates across a broader landscape of interventional medical devices, from cardiovascular to neuromodulation. Its success with Farapulse pulsed field ablation and strong cardiovascular sales (+26% in first-quarter 2025) highlight its diversified growth drivers. Growth & Performance ISRG delivered robust first-quarter 2025 results: revenues grew 19% to $2.25 billion, adjusted net income rose 22% to $767.5 million, and adjusted EPS grew 21% to $1.81. Its projected procedure growth remains strong at 15-17% for the year, though margins may be pressured by tariffs. BSX also posted solid first-quarter 2025 earnings, with adjusted EPS of $0.75 and sales worth $4.66 billion, both beating expectations on the back of cardiovascular and medical-surgical divisions. For the second quarter of 2025, revenues are expected to grow by double digits, driven by PFA and other interventions. Estimates Comparison for ISRG & BSX The Zacks Consensus Estimate for ISRG's fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 6.8%, respectively. EPS estimates for 2025 and 2026 have trended southward over the past 60 days. ISRG Estimate Movement The Zacks Consensus Estimate for Boston Scientific's 2025 sales and EPS implies a year-over-year improvement of 16.4% and 15.9%, respectively. Moreover, EPS estimates for 2025 and 2026 have improved over the past 60 days. BSX Estimate Movement Cash & Cash Flow Intuitive Surgical maintains an exceptionally strong balance sheet, with $4.51 billion in cash and no debt as of the first quarter of 2025. The company generated free cash flow of around $465 million and operating cash flow of $582 million, driven by continued growth in da Vinci system procedures and high-margin recurring revenues from instruments and accessories. Boston Scientific, operates with a more leveraged profile. The company reported $725 million in cash and $11.31 billion in total debt, with a debt-to-equity ratio of nearly 50%. Despite this, BSX maintains strong cash generation, posting $541 million in operating cash flow and $354 million in free cash flow for the first quarter of 2025 alone. Its diversified product base, especially in cardiovascular and electrophysiology, supports ongoing growth and debt service. Risks & Operational Challenges ISRG is exposed to geopolitical and trade-related tariff risks — especially a 125% tariff on Chinese exports — which have led to margin revisions for 2025. Mitigation efforts include supply-chain adjustments and pricing flexibility. BSX contends with regulatory and legal exposures (notably from past medical-device recalls and mesh product lawsuits), but its diversified supply chain and global footprint help buffer macroeconomic pressures. ISRG or BSX: Which Is a Better Bet? For investors focused on explosive, category-leading growth in surgical robotics, ISRG may still be the superior choice. But those who prefer balanced exposure across med-tech segments with a steadier valuation profile might consider BSX as a more diversified, resilient option. Intuitive Surgical stands out for its pristine balance sheet, zero debt, and strong free cash flow, making it an appealing choice for investors prioritizing financial stability and growth. Boston Scientific's leveraged balance sheet is offset by a diversified product base and solid, consistent cash generation, positioning it as a resilient and innovative med-tech player for investors comfortable with moderate financial risk. Both companies currently carry a Zacks Rank #3 (Hold). However, if we go by the Zacks Style Score, BSX seems to be a better bet compared to ISRG. While ISRG has a Zacks Style Score of 'D', BSX's score is 'C', reflecting better growth potential. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Yahoo
4 days ago
- Health
- Yahoo
Mikin Patel, MD and Osman Ahmed, MD Join Joint & Vascular Institute
Former University of Chicago professors among nation's leading interventional radiology specialists LIBERTYVILLE, Ill., June 17, 2025--(BUSINESS WIRE)--Dr. Mikin V. Patel and Dr. Osman Ahmed have co-founded the Joint & Vascular Institute. Both doctors specialize in performing minimally invasive imaging-guided procedures to treat a multitude of diseases and health conditions, many of which once required open surgery. Dr. Patel completed his diagnostic radiology residency at the University of Chicago Medical Center and a fellowship in Vascular and Interventional Radiology at Northwestern McGaw Medical Center. After working at the University of Arizona Medical Center, he returned to the University of Chicago as an Assistant Professor of Vascular and Interventional Radiology, where he taught other physicians how to treat patients effectively using advanced endovascular techniques. "I'm excited to offer academic-level care to patients in the convenience of a patient-focused outpatient clinic," Dr. Patel said. Dr. Ahmed received his medical degree from the University of Illinois College of Medicine. He completed his diagnostic residency at the University of Chicago and his fellowship training in vascular and interventional radiology at Stanford University School of Medicine. In addition to his clinical expertise, Dr. Ahmed is a pioneer in the field of musculoskeletal embolization in the United States and has been published in several peer-reviewed journals. Dr. Ahmed added: "Vascular and interventional radiology is one of the fastest growing and most innovative fields in medicine. We provide minimally invasive options to patients and their doctors in the greater Chicago area that, in many cases, are safer, yet just as effective, as their surgical alternatives." The doctors' expertise includes minimally invasive treatments for cancer, vascular disease, uterine fibroids, benign prostatic hyperplasia (enlarged prostate), internal hemorrhoids, and thyroid nodules, as well as orthopedic embolization procedures that treat conditions such as adhesive capsulitis (frozen shoulder), plantar fasciitis, knee osteoarthritis and hip bursitis/osteoarthritis. Unlike surgery, vascular and interventional radiology procedures to treat these conditions are performed on an outpatient basis, require no hospitalization or general anesthesia, carry less risk and offer a much faster recovery. Additionally, they are less expensive than surgery and covered by most insurance plans and Medicare. Joint & Vascular Institute Joint & Vascular Institute is dedicated to offering innovative, minimally invasive solutions to help patients achieve relief from pain and improve overall health. Serving the northern Chicago area, the practice specializes in advanced procedures designed to treat a variety of conditions without the need for traditional surgery, helping patients recover quickly and resume their daily lives. For more information visit View source version on Contacts Media Contact: Mikin Patel, MD Joint & Vascular Institute847-584-3959mvp@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
Global Interventional Treatment Materials Market Trends, Growth Drivers and Future Outlook
Interventional Treatment Materials Market Outlook 2025-2034 Luton, Bedfordshire, United Kingdom, May 20, 2025 (GLOBE NEWSWIRE) -- Introduction The global interventional treatment materials market encompasses the medical devices and materials used in minimally invasive therapeutic procedures. These include essential tools such as catheters, stents, and guidewires, which enable doctors to perform interventions inside the body without open surgery. Over the past decade, there has been a marked shift in healthcare towards minimally invasive interventions due to their benefits in reducing patient trauma, shortening recovery times, and improving outcomes. This trend has fueled growth in the interventional materials market. In 2024, the global market size is estimated around $10.5 billion, and it is on track to expand steadily at a mid-single-digit annual growth rate. By 2034, the market is projected to reach approximately $18 billion, reflecting robust demand and continuous innovation in this field. This report provides a comprehensive analysis of the market's current state, recent developments, key players, and segment-wise insights (by product type, application, end user, technology, and distribution channel), along with forecasts through 2034. Get a Sample PDF Brochure: Market Overview The interventional treatment materials market is experiencing strong growth driven by a confluence of demographic and technological factors. An aging global population and the rising prevalence of chronic diseases are key growth drivers. As conditions like cardiovascular disease, diabetes, and cancer become more common, the need for effective, less invasive treatment options grows. Interventional procedures – such as angioplasty for heart disease or embolization for cancer – often rely on specialized catheters, guidewires, and stents, directly boosting demand for these materials. Additionally, ongoing technological advancements in medical devices are propelling the market forward. Innovations in material science (e.g. more flexible, biocompatible alloys and polymers) have led to next-generation products like drug-eluting stents, bioresorbable stents, and coated balloons that improve patient outcomes. The push toward minimally invasive surgery across medical disciplines has made these interventional tools indispensable in modern treatment protocols. Key Market Drivers and Trends Rising Chronic Disease Prevalence: The increasing incidence of cardiovascular diseases, cancers, and other chronic conditions worldwide is a fundamental driver. More patients with blocked arteries, tumors, or other conditions means a higher volume of interventions (like angioplasties or tumor embolizations) that require these materials. Shift to Minimally Invasive Procedures: Both patients and providers prefer less invasive treatments when available. The success of angioplasty/stenting over open-heart surgery, for example, exemplifies this shift. This drives demand for interventional devices (catheters, stents, guidewires) across cardiology, oncology, orthopedics, and beyond. Technological Innovation: Rapid advancements are improving device performance. Examples include drug-eluting and bioresorbable stents that reduce long-term complications, smart guidewires with better torque control, and catheters with improved coatings for navigation. New materials (like nitinol alloys for flexibility and shape memory) and designs are expanding the capabilities of interventional tools. Improved Imaging and Navigation: Better imaging techniques (high-resolution fluoroscopy, intravascular ultrasound, OCT, etc.) and navigation systems allow more complex procedures to be done interventionally. This in turn expands the scope of what can be treated with catheter-based approaches, indirectly boosting the market for the necessary materials. Growing Healthcare Investment: Many countries are increasing healthcare expenditures. There is a general trend of hospitals upgrading cath labs and interventional suites, especially in developing markets. As infrastructure improves, the volume of procedures (and thus material usage) rises. An expanding middle class in emerging economies is also driving demand for advanced treatments that utilize these devices. Challenges and Restraints High Device Costs: Advanced interventional devices can be expensive (for example, the latest generation drug-eluting stents or robotic catheter systems). In regions with constrained healthcare budgets or in low-resource hospitals, cost can be a barrier to adoption. Some providers may opt for older, cheaper alternatives or limit use to critical cases. Pricing Pressure and Competition: With many players in the market, competition is intense. Hospitals and purchasing groups often negotiate price reductions, which pressures manufacturers' profit margins. Companies must balance affordability with recouping R&D investments. Regulatory and Compliance Hurdles: Developing a new stent or catheter and getting it approved by regulators (like the FDA or CE marking in Europe) is a lengthy process. Strict safety and efficacy requirements are essential for patient safety but can delay time-to-market. Additionally, variations in regulatory standards across countries can complicate global product rollout. Supply Chain Vulnerabilities: The pandemic years highlighted issues in global supply chains for medical components. Shortages of certain plastics or metals, or delays in sterilization services, have impacted device availability at times. Ensuring a robust supply chain and redundancy is now a focus area for companies, but disruptions remain a risk. Clinical Adoption and Training: Some new technologies (e.g. robotic-assisted systems or novel imaging-guided techniques) have a learning curve. If physicians are not trained or comfortable with a new device, they may be slower to adopt it. Training programs and demonstrable improvements in outcomes are needed to convince practitioners to switch from established methods. Browse full Report - Market Segmentation by Product Type Stents – 45% of market share: Stents represent the largest product segment. They are vital in cardiovascular interventions, especially in treating coronary artery disease and peripheral arterial disease by propping open narrowed arteries. Their dominance is due to the high volume of cardiac procedures worldwide. In addition to vascular stents, this category includes stent grafts and other scaffolding implants used in gastroenterology or urology (e.g., bile duct stents, ureteral stents). Balloon Catheters – 25% of market share: Catheters are the second-largest segment, with balloon angioplasty catheters being a major subcategory (often counted separately because of their significance in opening blood vessels during angioplasty). Catheters are versatile tubes used across virtually all interventional procedures to deliver fluids, inflate balloons, deploy stents, or perform ablations. Guidewires – 20% of market share: Guidewires are the thin, flexible wires that physicians first insert and navigate through the anatomy, paving the way for catheters. While they account for a slightly smaller share of revenue relative to stents and catheters, guidewires are indispensable in almost every interventional procedure. They tend to be lower-cost per unit than stents, which partly explains their smaller share of the market value, but in terms of volume, they are used in huge numbers. Table: Global Market Share by Product Type (2024) Product Type Approx. Market Share (2024) Segment Characteristics & Outlook Stents 45% Largest segment driven by high-volume cardiovascular procedures; continual innovation in drug-eluting and bioresorbable stents will sustain growth. Balloon Catheters 25% Key tools for angioplasty and other interventions; new variants like drug-coated balloons boost utility and market demand. Guidewires 20% Ubiquitous support devices for navigation; advancements in materials (e.g. nitinol) improve performance and support steady growth. Others 10% (E.g. sheaths, coils, etc.) A collection of other interventional tools; growing with niche applications but relatively smaller share. Market Segmentation by Application Cardiology – 60% of market share: Cardiology (including interventional cardiology and endovascular procedures for peripheral vascular disease) is the largest application segment for interventional materials. The majority of catheters, guidewires, and stents produced globally are used in cardiovascular procedures. Oncology – 15% of market share: Oncology is an emerging and fast-growing application for interventional materials, often referred to as interventional oncology. This involves minimally invasive procedures to diagnose or treat cancers. Examples include tumor embolization (blocking blood supply to a tumor by injecting embolic agents via catheters), radioembolization (delivering radioactive microspheres through catheters to a tumor site, such as in liver cancer), and ablation procedures (using needle-like probes inserted percutaneously to destroy tumors with extreme heat, cold, or electric fields – some of these probes are guided by catheters or via similar techniques). Orthopedics – 10% of market share: Orthopedic applications of interventional materials are more limited in scope compared to cardiology or oncology, but they represent a growing niche. In orthopedics, 'interventional' procedures often mean minimally invasive treatments of bone or spine conditions. Table: Global Market Share by Application (2024) Application Area Approx. Share (2024) Notes on Usage and Growth Drivers Cardiology 60% Largest segment. Includes coronary and peripheral artery interventions; driven by widespread cardiovascular disease and established efficacy of stents and angioplasty. Oncology 15% Growing segment. Encompasses interventional oncology procedures (tumor embolization, ablation); fueled by rising cancer cases and adoption of minimally invasive tumor therapies. Orthopedics 10% Niche but expanding. Includes spinal interventions (e.g. kyphoplasty) and pain management; growth tied to aging populations and demand for non-surgical orthopedic treatments. Other Applications 15% (GI, Urology, Neuro, etc.) Various other uses of interventional materials; important in their fields (e.g. biliary stents, neurovascular coils) but individually smaller portions of the market. Market Segmentation by End User Hospitals – 60% of demand: Hospitals are the primary end users of interventional materials, accounting for roughly 60% of the market demand. This is because hospitals, especially large acute-care and specialty hospitals, perform the majority of complex interventional procedures. They have dedicated catheterization labs, interventional radiology suites, operating rooms, and the full range of support services (ICUs, emergency care) necessary for high-risk interventions. Ambulatory Surgical Centers (ASCs) – 30% of demand: ASCs are facilities that provide same-day surgical care, including diagnostic and preventive procedures, outside of a hospital setting. Over the last decade, many interventional procedures have started migrating to ASCs because of cost-effectiveness and efficiency. Clinics and Specialty Centers – 10% of demand: This segment includes smaller clinics, physician offices, or specialty centers that perform minimally invasive procedures. Table: Global Market Share by End User (2024) End User Approx. Usage Share (2024) Commentary Hospitals 60% Major tertiary hospitals perform the bulk of complex interventional procedures; they adopt new technologies quickly and drive most of the demand. Ambulatory Surgical Centers (ASCs) 30% ASCs handle many routine or moderate-risk interventions on an outpatient basis; their role is growing as healthcare shifts toward cost-effective same-day procedures. Clinics & Specialty Centers 10% Smaller clinics perform limited types of interventions (e.g. vein treatments, pain management); collectively a smaller share, with gradual growth as office-based labs increase. Market Segmentation by Technology Balloon Angioplasty Techniques: This refers to the classic technology of using balloon catheters to dilate vessels or spaces in the body. Balloon angioplasty is a cornerstone of interventional cardiology and is also used in other fields (like opening a narrowed bile duct or a peripheral artery). In terms of market impact, balloon angioplasty is extremely prevalent – a large proportion of interventional procedures involve a balloon catheter at some stage. Robotic-Assisted Interventions: Robotic-assisted technology in interventional procedures is an exciting and relatively new segment. Robotic catheter navigation systems (such as the CorPath system for vascular procedures or robotic systems for neurovascular and peripheral interventions) allow physicians to perform procedures with robotic precision and even remotely in some cases. Advanced Imaging-Guided Techniques: Imaging is an integral part of all interventional procedures – standard practice uses fluoroscopy (real-time X-ray) for guidance in vascular interventions, and ultrasound or CT for certain others. Here, we highlight the increasing use of advanced imaging techniques and image-guided adjuncts that are transforming interventions. This includes technologies like Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT), where miniaturized imaging probes (often on a catheter or guidewire) are used inside blood vessels to visualize plaques and stent deployment; fusion imaging that combines pre-op CT/MRI with live fluoroscopy for better guidance; and even augmented reality or 3D navigation systems for complex anatomy. Market Segmentation by Distribution Channel Direct Sales – 55% of market sales: In direct sales, medical device companies sell their products straight to hospitals, clinics, or healthcare systems without intermediaries. Over half of the global interventional materials market (by revenue) is supplied via direct sales. Major manufacturers (especially the large ones with global operations) maintain their own sales and distribution networks to serve big clients like hospital systems. Direct sales allow manufacturers to have closer relationships with physicians and hospitals, offer specialized training or support, and handle pricing and contracts directly. Distributors – 30% of market sales: Distributors are intermediary companies that purchase medical products from manufacturers and then supply them to healthcare providers. Roughly 30% of interventional materials reach end users through distributors. This channel is vital for covering geographically broad or hard-to-reach markets and for servicing smaller hospitals and clinics that may not have direct accounts with big manufacturers. Online and Other Channels – 15% of market sales: Though not explicitly listed in the segmentation request, it's worth noting the rise of online procurement platforms and other non-traditional channels, which currently account for roughly 15% of sales. Some hospitals use online marketplaces or centralized procurement systems to order medical supplies (including certain standard catheters or consumables). Table: Distribution Channels for Interventional Materials (Global, 2024) Distribution Channel Share of Sales (2024) Characteristics and Trends Direct Sales 55% Manufacturers selling directly to hospitals/ASCs; offers control over client relationships and often used for major accounts and advanced products. Distributors 30% Intermediaries that supply products to healthcare providers; crucial for broad market coverage and smaller facilities, especially in emerging markets or regions where manufacturers lack direct presence. Online/E-procurement 15% Web-based ordering platforms and group purchasing; growing in use for standard supplies, though high-touch device sales still rely on direct rep support. Buy Now - Key Players and Competitive Landscape Medtronic plc Boston Scientific Corporation Abbott Laboratories Johnson & Johnson (J&J) Terumo Corporation Cook Medical B. Braun Melsungen AG BD (Becton, Dickinson and Company) Philips Healthcare Stryker Corporation W. L. Gore & Associates (Gore Medical) Merit Medical Systems AngioDynamics, Inc. Asahi Intecc Co., Ltd. Recent Developments (2022–2025) Medtronic – October 2023: Product Launch – Medtronic launched a next-generation catheter-based interventional system aimed at enhancing minimally invasive surgeries. This new system integrates advanced imaging capabilities directly into the catheter platform, allowing surgeons to visualize and navigate with greater precision during procedures. The catheter also features improved maneuverability with a more responsive design. Boston Scientific – September 2023: Acquisition – Boston Scientific announced the acquisition of a promising startup specializing in next-generation interventional radiology tools. The startup's portfolio included advanced microcatheters and novel guidewire technology that utilize smart sensors for real-time feedback during procedures. Abbott Laboratories – August 2023: Regulatory Approval – Abbott received U.S. FDA approval for a new interventional device aimed at cardiovascular applications. The device – a novel drug-eluting scaffold (stent) – is notable for its enhanced drug delivery mechanism and a slimmer profile. Clinical trials demonstrated excellent efficacy in keeping arteries open with a favorable safety profile. Johnson & Johnson – June 2023: Strategic Partnership – Johnson & Johnson (through its medical device division) entered into a strategic partnership with a technology company specializing in artificial intelligence (AI) and machine learning for healthcare. The goal of the partnership is to integrate AI-driven analytics into interventional procedures. Concretely, they are working on software that can analyze live imaging feeds and patient data during an intervention to provide decision support – for example, suggesting optimal catheter paths, detecting subtle changes in blood flow, or predicting complications. By combining J&J's medical expertise with the tech company's AI algorithms, the collaboration aims to create smarter interventional systems that help physicians plan and execute procedures with enhanced precision. Stryker Corporation – May 2023: Expansion Initiative – Stryker announced the expansion of one of its manufacturing facilities in India to increase production capacity for interventional treatment materials. This expansion is in response to growing demand in the Asia-Pacific region for interventional products, including Stryker's neurovascular stents and catheters. By scaling up production in India, Stryker aims to serve regional markets more efficiently, reduce costs, and mitigate supply chain risks. Johnson & Johnson – November 2022: Major Acquisition – In late 2022, J&J made headlines by acquiring Abiomed, a company well-known for its Impella heart pump devices, in a multi-billion dollar deal. While Abiomed's products (percutaneous heart pumps) are somewhat adjacent to the classic 'catheter, stent, guidewire' trio, they are used in interventional cardiology for supporting patients with severe heart failure or during high-risk angioplasty. This acquisition by J&J signaled the company's re-entrance into frontline interventional cardiology devices in a big way. Market Recovery Post-Pandemic (2022–2023): After the COVID-19 pandemic disruptions of 2020-2021, the years 2022 and 2023 saw a robust recovery in elective interventional procedure volumes. Hospitals that had postponed non-urgent cardiovascular and other interventions caught up with backlog, which led to a surge in demand for stents, catheters, and related supplies. Companies reported improved sales, especially in the second half of 2022, as cath labs returned to near-full operation. Technology Integration and Minor Players (2024): As we moved into 2024, there's an ongoing wave of integration of digital technology in interventional products. Smaller companies and startups introduced innovations like catheters with built-in sensors that can provide data on pressure or blood flow from within vessels, and guidewires that can act as imaging tools (combining guidance and diagnostics). This report is also available in the following languages : Japanese (介入治療材料市場), Korean (중재 치료 재료 시장), Chinese (介入治疗材料市场), French (Marché des matériaux de traitement interventionnel), German (Markt für interventionelle Behandlungsmaterialien), and Italian (Mercato dei materiali per il trattamento interventistico), etc. Download Full PDF Sample Copy of Market Report @ Related reports - New Medical Dressings Market The global new medical dressings market is valued at an estimated $8.5 billion in 2024, reflecting a steady demand driven by advancements in wound care technologies and an increasing prevalence of chronic wounds. The market is projected to reach approximately $14 billion by 2034, showcasing significant growth opportunities over the next decade. Drug Dispensing Robot Market The global drug dispensing robot market is valued at approximately $3.2 billion in 2024 and is anticipated to reach $7.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 9.1% during the forecast period from 2025 to 2034. Digital All-In-One Operating Room System Market The global digital all-in-one operating room system market is poised for significant growth, with an estimated market value of $4.5 billion in 2024. This market is projected to reach approximately $10.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 9.1% during the forecast period from 2025 to 2034. Single Use Transfusion Sets Market The global single-use transfusion sets market is valued at approximately $2.5 billion in 2024, with expectations to reach around $4.2 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period from 2025 to 2034. Regenerative Dermal Fillers Market The global regenerative dermal fillers market is valued at approximately $6.3 billion in 2024 and is projected to reach around $10.5 billion by 2034, reflecting robust growth opportunities within the sector. This forecast indicates a Compound Annual Growth Rate (CAGR) of about 5.2% from 2025 to 2034. Photonic Medical Equipment Market The global photonic medical equipment market is valued at approximately $15.4 billion in 2024, driven by advancements in laser and imaging technologies that enhance diagnostic and therapeutic capabilities. The market is anticipated to reach around $38 billion by 2034, reflecting significant growth opportunities as the healthcare sector increasingly adopts minimally invasive procedures. This translates to a robust Compound Annual Growth Rate (CAGR) of approximately 9.2% during the forecast period from 2025 to 2034. Freezing Fat Reduction Apparatus Market The global freezing fat reduction apparatus market is projected to reach a value of approximately $800 million in 2024, reflecting a robust demand driven by rising interest in non-invasive body contouring procedures. The market is expected to experience substantial growth, with a forecasted value of around $1.6 billion by 2034, representing a Compound Annual Growth Rate (CAGR) of about 7.5% during the period from 2025 to 2034. Intelligent Blood Collection Management System Market The global Intelligent Blood Collection Management System (IBCMS) market is valued at approximately $2.5 billion in 2024, with projections suggesting a robust growth trajectory that could elevate its value to around $5 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of approximately 8% during the forecast period from 2025 to 2034. Negative Pressure Diverter Market The global negative pressure diverter market is valued at approximately $3 billion in 2024. As healthcare facilities prioritize infection control and patient safety, the market is poised for robust growth. The projected market value for the period 2025–2034 is estimated to reach around $5 billion, reflecting a Compound Annual Growth Rate (CAGR) of approximately 6.2%. Medical CT Film Market The global medical CT film market is poised for robust growth, valued at approximately $1.2 billion in 2024. This sector is projected to expand at a CAGR of 6.5% from 2025 to 2034, reaching an estimated market value of around $2.3 billion by the end of the forecast period. 3A Sanitary Fixtures for Pharma & Biotech Market The global 3A sanitary fixtures market for the pharmaceutical and biotech sectors is valued at approximately $3.2 billion in 2024, with projections indicating a robust expansion, reaching an estimated $5.6 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of around 6.2% during the 2025-2034 forecast period. Shielded Isolators and Hot Cells Market The global shielded isolators and hot cells market is valued at approximately $1.2 billion in 2024, with expectations to reach around $2.4 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 7.4% during the forecast period from 2025 to 2034. Bifidus Product Market The global bifidus product market is estimated to reach approximately $1.3 billion in 2024, driven by increasing health consciousness and the rising demand for probiotic-rich foods. The market is projected to grow at a compound annual growth rate (CAGR) of 8.4%, reaching an estimated value of $2.7 billion by 2034. Molecular Diagnostic Kits Market The global molecular diagnostic kits market is valued at approximately $9.3 billion in 2024, reflecting significant advancements in biotechnology and increasing demand for rapid and accurate diagnostics. The market is projected to reach around $15.6 billion by 2034, driven by heightened adoption of personalized medicine and growing prevalence of infectious diseases. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 6.0%. Medical Reusable Sterilization Container Market The global market for medical reusable sterilization containers is projected to be valued at approximately $1.2 billion in 2024. This market is expected to experience substantial growth, with a projected value of around $2.3 billion by 2034. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 7.1%. Ventilator Humidifiers Market The global ventilator humidifiers market is projected to reach a value of approximately $1.2 billion in 2024, driven by increasing demand for respiratory care across healthcare facilities. The market is expected to grow significantly, with an estimated value of $2.5 billion by 2034, corresponding to a robust Compound Annual Growth Rate (CAGR) of around 8.5% during the forecast period from 2025 to 2034. Prefilled Humidifiers Market the global market for prefilled humidifiers is valued at approximately $2.1 billion, driven by rising consumer demand for healthier indoor air quality and growing awareness of respiratory ailments. The market is projected to expand significantly, with an estimated value of $3.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period from 2025 to 2034. Prefilled Bubble Humidifiers Market The global prefilled bubble humidifier market is projected to reach a value of approximately $1.2 billion in 2024, driven by an increasing prevalence of respiratory diseases and the growing need for effective humidification in medical settings. The market is expected to experience significant growth, with a projected value of around $2.5 billion by 2034 BPDA Market The global Business Process Digital Automation (BPDA) market is poised for substantial growth, with an estimated value of approximately $6.5 billion in 2024. This momentum is expected to continue, leading to a projected market value of around $15 billion by 2034. This growth corresponds to a robust Compound Annual Growth Rate (CAGR) of approximately 9% over the forecast period from 2025 to 2034. Near Infrared Medical Fluorescence Imaging System Market The global near-infrared (NIR) medical fluorescence imaging system market is valued at approximately $1.3 billion in 2024. It is projected to reach around $3.1 billion by 2034, reflecting significant growth driven by advancements in imaging technology, increasing adoption of NIR imaging in surgical procedures, and the rising prevalence of cancer and other diseases that necessitate precise imaging techniques. The market is expected to grow at a compound annual growth rate (CAGR) of 9% during the forecast period from 2025 to 2034. CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
